Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
Portfolio Pulse from
Natera, Inc. has announced that its Signatera test has received Medicare coverage for use in surveillance of non-small cell lung cancer (NSCLC) patients. This coverage is provided by the CMS's Molecular Diagnostics Services Program and applies to patients with stage I-III NSCLC.
February 25, 2025 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Natera's Signatera test has received Medicare coverage for NSCLC surveillance, potentially increasing its market reach and revenue.
The Medicare coverage for Natera's Signatera test in NSCLC surveillance is a significant regulatory milestone. It expands the test's accessibility to a broader patient base, likely increasing demand and revenue. This positive development is expected to have a favorable impact on Natera's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100